- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | NSE - LakeShore Biopharma Co., Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| 04.11. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.09. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.09.2025 | 883 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 30.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.09.2025ISIN NameCA8875221001 TINKA... ► Artikel lesen | |
| 22.09. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.09. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting | 157 | PR Newswire | BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 12.09. | LakeShore Biopharma faces Nasdaq delisting after failing to meet bid price rule | 2 | Investing.com | ||
| 12.09. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq | 805 | PR Newswire | BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 10.09. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.09. | LakeShore Biopharma appoints advisors to evaluate buyout proposal | 1 | Investing.com | ||
| 29.08. | LakeShore Biopharma Board Reviewing Revised $0.86-Per-Share Buyout Proposal | - | RTTNews | ||
| 28.08. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee | 477 | PR Newswire | BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 18.08. | LakeShore Biopharma receives $0.86/share buyout proposal from Oceanpine Capital | 2 | Seeking Alpha | ||
| 18.08. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.08. | Oceanpine Capital unterbreitet Übernahmeangebot für LakeShore Biopharma zu 0,86 US-Dollar je Aktie | 1 | Investing.com Deutsch | ||
| 18.08. | Oceanpine Capital proposes to acquire LakeShore Biopharma for $0.86 per share | 1 | Investing.com | ||
| 18.08. | LakeShore Biopharma Receives Proposal Letter From Oceanpine Capital | 1 | RTTNews | ||
| 18.08. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company | 155 | PR Newswire | BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 01.08. | LakeShore Biopharma GAAP EPS of -RMB5.22, revenue of RMB615M | 1 | Seeking Alpha | ||
| 31.07. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Fiscal Year 2025 Financial Results | 84 | PR Newswire | Total revenue reached RMB615.0 million, representing 7.2% year-over-year growth
Gross profit rose to RMB507.2 million, up 11.3% year-over-year
Gross margin improved... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 104,24 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 20,190 | 0,00 % | Morning Market Movers: Olema Pharmaceuticals, LifeMD, Alpha Technology Group, Intellinetics See Big Swings | HELSINKI (dpa-AFX) - At 8:10 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 13,000 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| DISC MEDICINE | 89,74 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,84 | 0,00 % | TD Cowen reiterates Hold rating on Avidity Biosciences stock at $74 | ||
| TANGO THERAPEUTICS | 8,000 | +0,25 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights | - Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months- - Combination studies with RAS(ON) inhibitors ongoing, data anticipated... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 43,460 | 0,00 % | Mineralys Therapeutic: Aktie gibt nach umfangreichen Insiderverkäufen nach | ||
| ARCUTIS BIOTHERAPEUTICS | 27,280 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,385 | 0,00 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,160 | 0,00 % | Recursion's Incoming CEO Needs To Prove That AI Drug Development Can Pay Off | ||
| UPSTREAM BIO | 25,560 | 0,00 % | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| QIAGEN | 38,380 | +1,66 % | AIM WINNERS & LOSERS: CelLBxHealth rises on Qiagen deal | ||
| STRUCTURE THERAPEUTICS | 34,410 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)... ► Artikel lesen | |
| INVIVYD | 2,520 | 0,00 % | Invivyd prices $125M stock offering at $2.50 per share | ||
| PRAXIS PRECISION MEDICINES | 184,22 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen |
Das Unternehmen LAKESHORE BIOPHARMA CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,665 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.